COR at a glance
Cencora (COR, SEC CIK 1140859) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 25, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2025 (FY2025), Cencora (COR) reported revenue of $321.3 billion (up 9.3% from FY2024) and net income of $1.6 billion. Diluted EPS was $7.96.
- As of June 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Cencora (COR) shares worth $25.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Krikorian Lazarus on October 1, 2026 of 986 shares at $303.18 per share.
- In the last 90 days, COR insiders reported 0 open-market purchases ($0) and 4 open-market sales ($4.7M) on Form 4, a net sale of $4.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $321.3B
- +9.3% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$4.7M
- 13F holders
- 49 funds
- $25.6B · −1 vs prior quarter
- Latest 8-K
- Sep 25, 2026
- Item 7.01 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2025
Business Overview
- Core business: Pharmaceutical distribution competing with manufacturers, chain drugstores, specialty distributors, packaging, and healthcare technology firms
- Emphasized regulatory compliance due to new U.S. and EU laws (DSCSA, Falsified Medicines Directive, EU Critical Medicines Act, EU HTA Regulation effective Jan 2025)
- Strategic focus on managing risks from opioid regulation, drug pricing reforms (Inflation Reduction Act, OBBBA), and 340B pricing program disputes and pilot rebate models
- Two largest trade receivables (Walgreens/Boots and Evernorth) represent approx. 43% of net accounts receivable as of Sept 30, 2025
- Noteworthy: Adoption of EU HTA Regulation harmonizing drug assessments starts Jan 12, 2025, with potential major impact on reimbursement decisions and market access
Risk Factors
- Board oversight of cybersecurity delegated to Audit Committee and Compliance and Risk Committee with quarterly meetings and ongoing updates
- CDIO with 25+ years experience and CISO with 20+ years oversee cybersecurity risk management and incident response
- Extended Cyber Crisis Response Team leads containment, recovery, and communication during cyber incidents
- Cybersecurity risk identified by Enterprise Risk Management Team for Board-level oversight and regular risk monitoring
Management Discussion & Analysis
- Revenue $321.3B, up 9.3% YoY; U.S. Healthcare Solutions revenue $291.0B, up 9.7% ($25.6B increase); International Solutions $30.4B, up 6.1% ($1.7B increase)
- Operating margin total 0.82% approx. (operating income $2.63B / revenue $321.3B); U.S. Healthcare margin 1.23%, up 12 bps YoY; International margin decreased 9.1% YoY
- Best segment: U.S. Healthcare Solutions operating income $3.57B, up 21.8% ($639.8M increase); worst segment: International Healthcare Solutions operating income $648M, down 9.1% ($65.1M decrease)
- Cash from operations $3.9B in fiscal 2025, capex $668M; acquisitions $3.9B for RCA; dividends $437.1M paid; share repurchases $435.5M with $882.2M authorization remaining
- Management expects ~$900M capex in 2026; key risks include nonrenewal of customer contracts, opioid litigation payments of $4.3B over 13 years, interest rate and foreign currency exposure, inflation pressures, and geopolitical uncertainties
AI summary of the COR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $84.8B, up 5.1% YoY from $80.7B, driven by U.S. Healthcare Solutions growth
- U.S. Healthcare Solutions strongest segment: revenue $74.9B, up 4.9%; GLP-1 sales $2.3B, up 25.5%
- Gross margin 4.26% vs 3.60% YoY; operating margin 1.32% vs 1.08% YoY
- Operating cash flow $1.7B versus $0.7B YoY; $3.0B senior notes and $1.5B term loans issued for OneOncology
- Outlook: GLP-1 demand supports growth; headwinds include generic conversions, pricing pressure, reimbursement pressure, and customer consolidation
Risk Factors
- No risk-factors section provided; excerpt covers issuer share repurchases only
AI summary of the COR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Standard Regulation FD liability disclaimer under Exchange Act Section 18
- Disclosure not incorporated into other Securities Act or Exchange Act filings unless expressly referenced
Item EX-99.1: Item EX-99.1
- Robert E. Sanchez elected independent director, effective October 1, 2026
- Former Ryder Chair and CEO brings public-company leadership and logistics expertise
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Robert E. Sanchez appointed Cencora director effective October 1, 2026
- Board expands from 10 to 11 members, increasing governance capacity and shareholder voting complexity
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Lorence H. Kim, M.D. resigned from Cencora’s Board effective August 13, 2026
- Departure tied to his appointment as CFO of Commonwealth Fusion Systems
Item 7.01: Regulation FD Disclosure
- Walgreens-related volume outside the prime vendor agreement began shifting away July 1, 2026
- Prime vendor agreement unchanged and still represents the vast majority of Cencora’s Walgreens business
AI summaries of COR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for COR
Don't miss the next COR filing
- Alerts as it files. A push when COR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut COR, by share count.
- Ask anything. An AI agent that reads every COR filing and answers with sources.
COR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Krikorian Lazarus | Sell | Oct 1, 2026 | 986 | $303.18 |
| SANCHEZ ROBERT E | A | Oct 1, 2026 | 275 | - |
| GREENBERG LON R | Sell | Sep 16, 2026 | 1,280 | $321.30 |
| Krikorian Lazarus | Sell | Sep 1, 2026 | 985 | $325.97 |
| Campbell Elizabeth S | Sell | Aug 24, 2026 | 11,300.471 | $324.12 |
| Tyler Lauren M | A | Jul 31, 2026 | 97 | $311.34 |
| Cooper Ellen | A | Jul 31, 2026 | 97 | $311.34 |
| NALLY DENNIS M | A | Jul 31, 2026 | 113 | $311.34 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $294.0B | $321.3B |
| Gross Profit | - | $9.9B | $11.5B |
| Operating Income | - | $2.2B | $2.6B |
| Net Income | - | $1.5B | $1.6B |
| Gross Margin | - | 3.4% | 3.6% |
| Op. Margin | - | 0.7% | 0.8% |
| Net Margin | - | 0.5% | 0.5% |
| Balance Sheet | |||
| Total Assets | $62.6B | $67.1B | $76.6B |
| Equity | $522.0M | $645.9M | $1.5B |
| ROE | - | 233.6% | 103.1% |
| Per Share | |||
| EPS | - | $7.53 | $7.96 |
| Cash Flow | |||
| Operating CF | - | $3.5B | $3.9B |
| CapEx | - | $487.2M | $668.0M |
Source: XBRL data in Cencora (COR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate COR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 49 | $25.65B |
| Q1 2026 | 50 | $30.18B |
| Q4 2025 | 50 | $32.11B |
| Q3 2025 | 54 | $31.94B |
| Q2 2025 | 50 | $29.05B |
| Q1 2025 | 48 | $18.65B |
| Q4 2024 | 41 | $11.53B |
| Q3 2024 | 35 | $5.51B |
- JPMorgan Chase & Co+1.06M (+22%)
- Millennium Management+575.6K (+154%)
- Citadel Advisors LLC+568.8K (+71%)
- Dimensional Fund Advisors+91.4K (+6%)
- State Street Corp+83.4K (+1%)
- FMR LLC (Fidelity)−2.56M (-38%)
- Invesco Ltd−1.97M (-49%)
- BlackRock−1.73M (-9%)
- Morgan Stanley−445.6K (-10%)
- Bank of America Corp−404.5K (-10%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 377 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
COR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
Related Health Care companies
- CAH · Cardinal HealthWholesale-Drugs, Proprietaries & Druggists' Sundries
- HLF · HERBALIFE LTD.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- MCK · McKesson CorporationWholesale-Drugs, Proprietaries & Druggists' Sundries
- NUS · NU SKIN ENTERPRISES, INC.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
COR SEC filings: frequently asked questions
Are COR insiders buying or selling?
In the last 90 days, Cencora (COR) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $4.7 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold COR stock?
As of June 30, 2026, the largest Cencora (COR) holders among the 13F filers tracked by SignalX were BlackRock ($5.2 billion), Vanguard Capital Management LLC ($3.5 billion), Vanguard Portfolio Management LLC ($2.7 billion), State Street Corp ($2.6 billion), T. Rowe Price Group ($2.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was COR's revenue in fiscal year 2025?
For the fiscal year ended September 30, 2025 (FY2025), Cencora (COR) reported revenue of $321.3 billion (up 9.3% from FY2024) and net income of $1.6 billion. Diluted EPS was $7.96. The figures come from the XBRL data in the 10-K.
What are the main risks in COR's latest 10-K?
In the 10-K filed November 25, 2025, Cencora (COR) flagged: Board oversight of cybersecurity delegated to Audit Committee and Compliance and Risk Committee with quarterly meetings and ongoing updates. CDIO with 25+ years experience and CISO with 20+ years oversee cybersecurity risk management and incident response. (AI summary of the Risk Factors section.)
What did COR report in its latest 8-K?
Cencora (COR) filed an 8-K on September 25, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Standard Regulation FD liability disclaimer under Exchange Act Section 18.
What are the latest COR SEC filings?
Cencora (COR) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 25, 2026 and a Form 4 insider filing on October 5, 2026.
What is COR's SEC CIK number?
Cencora (COR)'s SEC Central Index Key (CIK) is 1140859. EDGAR lists every COR filing under that number.
Ask anything about COR
The research agent reads COR's filings, financials, insider trades and 13F holders, then answers with sources.